Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
23 studies found for:    Corticobasal Degeneration
Show Display Options
RSS Create an RSS feed from your search for:
Corticobasal Degeneration
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed
Has Results
A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration
Conditions: Progressive Supranuclear Palsy;   Corticobasal Degeneration
Intervention: Drug: Lithium
2 Completed Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers
Conditions: Progressive Supranuclear Palsy;   Corticobasal Degeneration
Interventions: Drug: 18F-AV-1451;   Drug: florbetapir F18
3 Completed Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration
Conditions: Progressive Supranuclear Palsy;   Corticobasal Degeneration;   Parkinsonism
Intervention:
4 Active, not recruiting 4 Repeat Tauopathy Neuroimaging Initiative
Conditions: Progressive Supranuclear Palsy;   Corticobasal Degeneration
Intervention: Other: Observational Study
5 Recruiting PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK
Conditions: Progressive Supranuclear Palsy (PSP);   Corticobasal Degeneration;   Multiple System Atrophy (MSA)
Intervention:
6 Recruiting Safety Study of TPI-287 to Treat CBS and PSP
Conditions: Primary Four Repeat Tauopathies (4RT);   Corticobasal Syndrome (CBS);   Progressive Supranuclear Palsy (PSP);   Corticobasal Degeneration (CBD)
Interventions: Drug: TPI 287 2 mg/m2;   Drug: TPI-287 20 mg/m2;   Drug: Placebo;   Drug: TPI-287 6.3 mg/m2
7 Active, not recruiting Davunetide (AL-108) in Predicted Tauopathies - Pilot Study
Conditions: Predicted Tauopathies, Including:;   Progressive Supranuclear Palsy;   Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17;   Corticobasal Degeneration Syndrome;   Progressive Nonfluent Aphasia
Interventions: Drug: davunetide (AL-108, NAP);   Drug: Placebo nasal spray
8 Recruiting 4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2
Conditions: Corticobasal Degeneration (CBD);   Corticobasal Syndrome (CBS);   Cortical-basal Ganglionic Degeneration (CBGD);   Progressive Supranuclear Palsy (PSP);   Nonfluent Variant Primary Progressive Aphasia (nfvPPA);   Oligosymptomatic/Variant Progressive Supranuclear Palsy (o/vPSP)
Intervention: Other: Observational Study
9 Active, not recruiting Defining Phenotypes of Movement Disorders :Parkinson's Plus Disorders, PD,Essential Tremor, (ET),Cortical Basal Degeneration, (CBD),Multiple Systems Atrophy (MSA), Magnetoencephalography
Conditions: Essential Tremor;   Multiple System Atrophy;   Corticobasal Degeneration;   Supranuclear Palsy, Progressive
Intervention:
10 Recruiting Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)
Conditions: FTLD;   Progressive Supranuclear Palsy (PSP);   Frontotemporal Dementia (FTD);   Corticobasal Degeneration (CBD);   PPA Syndrome;   Behavioral Variant Frontotemporal Dementia (bvFTD);   Semantic Variant Primary Progressive Aphasia (svPPA);   Nonfluent Variant Primary Progressive Aphasia (nfvPPA);   FTD With Amyotrophic Lateral Sclerosis (FTD/ALS);   Amyotrophic Lateral Sclerosis (ALS);   Oligosymptomatic PSP (oPSP);   Corticobasal Syndrome (CBS)
Intervention:
11 Completed Effects of Coenzyme Q10 in PSP and CBD
Conditions: Progressive Supranuclear Palsy;   Neurological Disorders
Intervention: Drug: CoQ10
12 Recruiting Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition
Condition: Disinhibition Syndrome
Interventions: Drug: AVP-786;   Drug: Placebo
13 Completed The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography
Condition: Parkinson's Disease
Intervention: Drug: 18F-FDG
14 Recruiting Study for the Early Diagnosis of Parkinson's Disease
Condition: Parkinson's Disease, Idiopathic
Intervention:
15 Recruiting Parkinson's Disease, Diagnostic Observations (PADDO)
Conditions: Parkinson's Disease;   Atypical Parkinsonism
Intervention:
16 Unknown  Innovative Biomarkers in Alzheimer's Disease and Frontotemporal Dementia (FTD): Preventative and Personalized
Condition: Alzheimer's Disease
Intervention:
17 Completed Study of Tongue Pressures
Conditions: Deglutition Disorder;   Healthy
Intervention:
18 Active, not recruiting The Sunnybrook Dementia Study: Mapping Brain Changes in Alzheimer's, Vascular and Other Dementias
Condition: Dementia
Intervention:
19 Enrolling by invitation DaTSCAN Imaging in Aging and Neurodegenerative Disease
Conditions: Dementia;   Parkinsonism;   Mild Cognitive Impairment;   REM Sleep Behavior Disorder
Interventions: Drug: I-123 Ioflupane solution injection prior to SPECT scan (DaTscan);   Device: Single photon emission computed tomography (SPECT) scan
20 Recruiting Genetic Characterization of Movement Disorders and Dementias
Conditions: Ataxia;   Dystonia;   Parkinson's Disease;   Amyotrophic Lateral Sclerosis;   Corticobasal Degeneration;   Multiple System Atrophy;   Alzheimer's Disease;   Lewy Body Dementia;   Parkinson Disease-Dementia;   Dentatorubral-pallidoluysian Atrophy;   Creutzfeldt-Jakob Disease and Fatal Familial Insomnia;   Fragile X-associated Tremor/Ataxia Syndrome;   Krabbe's Disease;   Niemann-Pick Disease, Type C;   Neuronal Ceroid Lipofuscinosis
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-23) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.